JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Lisata Therapeutics

Geschlossen

4.54 -1.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.5

Max

4.55

Schlüsselkennzahlen

By Trading Economics

Angestellte

26

Dividenden

By Dow Jones

Nächstes Ergebnis

26. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

15M

35M

Vorheriger Eröffnungskurs

5.84

Vorheriger Schlusskurs

4.54

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Feb. 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8. Feb. 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8. Feb. 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8. Feb. 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Feb. 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8. Feb. 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8. Feb. 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8. Feb. 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8. Feb. 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7. Feb. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. Feb. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Feb. 2026, 02:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Money, High Anxiety -- Barrons.com

6. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. Feb. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. Feb. 2026, 21:17 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Feb. 2026, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. Feb. 2026, 21:13 UTC

Ergebnisse

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. Feb. 2026, 21:13 UTC

Ergebnisse

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. Feb. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. Feb. 2026, 20:34 UTC

Ergebnisse

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Finanzen

$

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
help-icon Live chat